[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560279":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":65,"collaborators":69,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":36,"studyType":87,"phases":88,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":50,"whyStopped":36,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"0.25 mg\u002Fkg RR-HNK","EXPERIMENTAL","OCD patients in this arm will receive 0.25mg\u002Fkg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.",[13],"Drug: RR-HNK\u002FHydroxynorketamine",{"label":15,"type":10,"description":16,"interventionNames":17},"0.5 mg\u002Fkg RR-HNK","OCD patients in this arm will receive 0.5mg\u002Fkg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo (Sterile Saline)","PLACEBO_COMPARATOR","OCD patients in this arm will receive sterile saline - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.",[23],"Drug: Placebo",[25,32],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","RR-HNK\u002FHydroxynorketamine","(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.",[9,15],[31],"(2R,6R)-Hydroxynorketamine",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Placebo","Sterile Saline",[19],null,[38],{"name":39,"affiliation":5,"role":40},"Carolyn Rodriguez, MD, PhD","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":36,"email":46},"Izzy Vo, BS","CONTACT","650-723-4095","ocdresearch@stanford.edu",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Stanford University School of Medicine","RECRUITING","Palo Alto","California","94305","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-122.14302,37.44188,{"lat":60,"lon":59},[63],{"name":64,"role":44,"phone":36,"phoneExt":36,"email":36},"Daniel Bello, BS",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"SPONSOR_INVESTIGATOR","Carolyn Rodriguez","Professor",[70],{"name":71,"class":72},"National Institutes of Health (NIH)","NIH","100560279","phase-1-pilot-study-of-rr-hnk-in-ocd-100560279",false,"NCT06575075","Pilot Study of RR-HNK in OCD","A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder","(HNKO)","Inclusion Criteria:\n\n* Ages 18-65\n* Meet the criteria for OCD diagnosis\n* Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI\u002FCBT) or or had refused these treatments for individual reasons\n* Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to ketamine\n* Any current or past medical\u002Fpsychiatric condition that makes participation unsafe in the opinion of the investigator or study physician\n* Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control\n* Lifetime history of deep brain stimulation","ALL","18 Years","65 Years",{"count":85,"type":86},45,"ESTIMATED","INTERVENTIONAL",[89,90],"PHASE1","PHASE2","The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.",[93],"Obsessive-Compulsive Disorder",[95,96,97,98],"OCD","AMPA receptor antagonist","hydroxynorketamine","ketamine metabolite","2026-03-03",{"date":101,"type":102},"2026-03-05","ACTUAL",{"date":104,"type":102},"2026-01-23",{"date":106,"type":86},"2029-11-30",{"name":67,"class":6},1]